<table>
<thead>
<tr>
<th>Site</th>
<th>Principle Investigator</th>
<th>Clinical Trial #</th>
<th>Drug/Study Tile/Brief Summary</th>
</tr>
</thead>
</table>
| Kidney Cancer   | Benjamin R. Lee, MD             | SWOG NCT03055013                        | **Immunotherapy (Nivolumab) to Treat Patients With Localized Kidney Cancer Undergoing Nephrectomy**  
This clinical trial compares nephrectomy (surgery to remove a kidney cancer) with or without nivolumab in patients with kidney cancer/tumor. Immunotheraphy, such as nivolumab, may help the body’s immune system attack the cancer and decrease the ability of cancers cells to grow and spread. |
| Prostate Cancer | Juan Chipollini, MD             | SWOG NCT03678025                        | **Standard Systemic Therapy (Hormonal treatment) With or Without Definitive Treatment (Robotic Surgery / Radiation) to treat Patients With Metastatic Prostate Cancer**  
This clinical trial focuses on response following standard therapy with or without definitive treatment (prostate removal surgery or radiation therapy) to treat prostate cancer which has spread outside the prostate, to other places in the body such as lymph nodes, bone, or other locations. In combination with robotic surgery or radiation therapy, together with systemic therapy for prostate cancer, this clinical trial may lower the chance of the cancer growing or spreading. |
| Bladder Cancer  | Juan Chipollini, MD / Hani Babiker, MD | SWOG NCT02844816 | **Atezolizumab (Anti PDL-1 antibody) in Treating Patients With Recurrent Bladder cancer (BCG-Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC))**  
This clinical trial studies how well the anti PDL-1 antibody works in treating patients with Bladder cancer which has come back and not responded to treatment with BCG (Treatment which typically is instilled in the bladder). Immunotherapy, such as atezolizumab, may help the body’s immune system attack the cancer, and may disrupt the cancer’s ability of tumor cells to grow and spread. |
| Prostate Cancer | Hani Babiker, MD                | NCT02987829                             | **Clinical Trial of a Androgen Receptor Antagonist (TRC253) in Metastatic Castration-resistant Prostate Cancer (mCRPC)**  
This is a multi-institutional, clinical trial where patients with mCRPC will receive medication orally to determine response against prostate cancer. |
| Prostate Cancer | Hani Babiker, MD                | NCT03511664                             | **Investigation of 177Lu-PSMA-617 (a targeted agent against PSMA - Prostate Specific Membrane Antigen positive prostate cancer cells) In Metastatic Castration-Resistant Prostate Cancer**  
The objective of this study is to compare survival in patients with PSMA-positive mCRPC who receive 177Lu-PSMA-617 plus standard of care. The theory is that this radioligand therapy creates a high binding target to deliver treatment directly to prostate cancer cells. It’s estimated that “80% of men with metastatic castration resistant prostate cancer cells express PSMA on their cancer cells. |
| Kidney Cancer   | Montaser Shaheen, MD            | NCT03428217                             | **CB-839 (A Glutaminase inhibitor) With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma**  
Glutaminase is a key enzyme that controls glutamine utilization, a metabolic pathway upregulated in Renal Cell Carcinoma and important for tumor proliferation and survival. This is a randomized study of CB-839 (telaglenastat) in combination with cabozantinib versus placebo with cabozantinib in patients with metastatic Renal Cell Carcinoma with a clear cell histology. |
| Bladder Cancer  | Hani Babiker, MD                | NCT03410693                             | **Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor) Positive Locally Advanced or Metastatic Urothelial Carcinoma**  
This is a randomized, open-label study to evaluate efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy. |

For more information contact the Urology clinic at (520) 694-4032 for appointment or send email to Dr. Juan Chipollini, Urology Oncology at email: juan.chipollini@bannerhealth.com